June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Presence of bevacizumab in the iridocorneal angle following intravitreal injection in a rat model
Author Affiliations & Notes
  • Orly Gal-Or
    Ophthalmology, Rabin Medical Center, Kfar Saba, Israel
  • Assaf Dotan
    Ophthalmology, Rabin Medical Center, Kfar Saba, Israel
  • Mor Dachbash
    Laboratory of Eye Research, Felsentatein Medical Research Center, Rabin Medical Center, Petach -Tikva, Israel
  • Yael Nisgav
    Laboratory of Eye Research, Felsentatein Medical Research Center, Rabin Medical Center, Petach -Tikva, Israel
  • Dov Weinberger
    Ophthalmology, Rabin Medical Center, Kfar Saba, Israel
    Laboratory of Eye Research, Felsentatein Medical Research Center, Rabin Medical Center, Petach -Tikva, Israel
  • Rita Ehrlich
    Ophthalmology, Rabin Medical Center, Kfar Saba, Israel
    Sackler School of Medicine, Tel -Aviv university, Tel-Aviv, Israel
  • Tami Livnat
    Laboratory of Eye Research, Felsentatein Medical Research Center, Rabin Medical Center, Petach -Tikva, Israel
    Sackler School of Medicine, Tel -Aviv university, Tel-Aviv, Israel
  • Footnotes
    Commercial Relationships Orly Gal-Or, None; Assaf Dotan, None; Mor Dachbash, None; Yael Nisgav, None; Dov Weinberger, None; Rita Ehrlich, None; Tami Livnat, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3270. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Orly Gal-Or, Assaf Dotan, Mor Dachbash, Yael Nisgav, Dov Weinberger, Rita Ehrlich, Tami Livnat; Presence of bevacizumab in the iridocorneal angle following intravitreal injection in a rat model. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3270.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Intravitreal anti vascular endothelial growth factor agents can cause sustained ocular hypertension in treated eyes. Our purpose was to investigate and characterize the presence of intravitreally injected Bevacizumab in the iridocorneal angle in a rat model.

Methods: Choroidal neovascularization was induced by diode laser photocoagulation on the right eye of twelve Brown Norway rats.<br /> Bevacizumab (25mg/ml) was injected intravitreally following 3 days.<br /> Immediately after Bevacizumab injection and 3,6,24 and 48 hours later, animals were euthanized for immunohfluorescence staining.<br /> Donkey anti-human IgG labeled with Alexa Fluor® 488 was used for Bevacizumab immunoreactivity detection. Anti CD31 antibody was used as a marker for schlemm's canal's (SC) endothelial cells.<br /> Untreated eyes were used as negative controls. We qualitatively analyzed the intensity of the immunohistochemistry staining.

Results: Bevacizumab immunoreactivity was found in the Trabecular Meshwork (TM) and Schlemm's canal (SC) immediately after injection, and declined in a decremented manner within the following hours.<br /> Forty eight hours from the injection no bevacizumab staining was detected in the iridocorneal angle structures.

Conclusions: Our study demonstrated Bevacizumab in iridocorneal angle structures after intravitreal injection in a rat model.<br /> Bevacizumab molecules were shown to pass within 48 hours through the iridocorneal angle starting immediately after intravitreal bevacizumab injection.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×